Updated on 27 October 2026
Exploitation and market-uptake partner for Cluster 1 Health 2027: digital health, AI, diagnostics and global-health (GACD) topics
Member of the Board at JCP Marketing et Communication AG
Schindellegi, Switzerland
About
JCP Marketing et Communication AG (Schindellegi, Switzerland; founded 1986) offers to lead or contribute to the communication, dissemination and exploitation (CDE) and market-uptake work of a Cluster 1 Health 2027 proposal. Switzerland is associated to Horizon Europe, so JCP takes part as a funded beneficiary.
What we bring to the consortium:
-
route to market and adoption: mapping of health-system buyers, users, procurement and reimbursement routes, together with the clinical and health-economics partners;
-
identification and characterisation of key exploitable results, exploitation strategy and business plans with the result owners;
-
stakeholder engagement with patient organisations, professional bodies, payers and industry, and clustering with related projects;
-
uptake and scale-up plans that continue after the project, including the Swiss and DACH markets;
-
for global-health topics (GACD, point-of-care diagnostics): identification, screening and onboarding of partners in Africa and India;
-
contribution to the impact section at proposal stage.
Relevant experience: health-technology deployment and market entry in India; living-lab partners secured in Kenya and Ghana for an EU-funded food-systems proposal; business development across Europe for an engineering company since 2006; research communication for a Swiss National Centre of Competence in Research; commercialisation of a university spin-off.
Topics of main interest: STAYHLTH-01, ENVHLTH-MISSCLIMA-03, DISEASE-01 and DISEASE-10 (GACD), TOOL-01, TOOL-04, TOOL-08 and IND-02.
Working languages English and German; also French. PIC 868000815. Contact: contact@jcp-marketing-event.ch
Topic
- Destination 1: HORIZON-HLTH-2027-01-STAYHLTH-01: Addressing disabilities through the life course to support independent living and inclusion
- Destination 2: HORIZON-HLTH-2027-01-ENVHLTH-MISSCLIMA-03: Tools and technologies to support health adaptation to climate change
- Destination 3: HORIZON-HLTH-2027-01-DISEASE-10: Prevention and management of chronic non-communicable diseases in children and young people (GACD)
- Destination 3: HORIZON-HLTH-2027-02-DISEASE-01-two-stage: Innovative healthcare interventions for non-communicable diseases
- Destination 5: HORIZON-HLTH-2027-02-TOOL-01-two-stage: Development of predictive biomarkers of disease progression and treatment response by using AI methodologies for chronic non-communicable diseases
- Destination 6: HORIZON-HLTH-2027-02-IND-02-two-stage: Portable and versatile Point-of-care diagnostics
- Destination 5: HORIZON-HLTH-2027-03-TOOL-08: Towards the next generation of frontier Artificial Intelligence models for healthcare
- Destination 5: HORIZON-HLTH-2027-03-TOOL-04: Virtual Human Twins (VHTs) for integrated clinical decision support in prevention and diagnosis
Type
- Partner seeks Consortium/Coordinator
Organisation
Similar opportunities
Project cooperation
SMEs seeking a Horizon Europe Health 2027 consortium: joint entry with an exploitation partner
- Consortium/Coordinator seeks Partners
- Destination 6: HORIZON-HLTH-2027-02-IND-02-two-stage: Portable and versatile Point-of-care diagnostics
- Destination 3: HORIZON-HLTH-2027-02-DISEASE-01-two-stage: Innovative healthcare interventions for non-communicable diseases
- Destination 4: HORIZON-HLTH-2027-01-CARE-02: Personalised approaches to reduce risks from Adverse Drug Reactions due to administration of multiple medications
- Destination 5: HORIZON-HLTH-2027-02-TOOL-01-two-stage: Development of predictive biomarkers of disease progression and treatment response by using AI methodologies for chronic non-communicable diseases
Eduard Garcia
Founder & Commercial Director at AxioTechBio
Paris, France
Project cooperation
Exploitation, go-to-market & industry partner for Cluster 1 Health 2027 consortia
- Partner seeks Consortium/Coordinator
- Destination 6: HORIZON-HLTH-2027-02-IND-02-two-stage: Portable and versatile Point-of-care diagnostics
- Destination 3: HORIZON-HLTH-2027-02-DISEASE-01-two-stage: Innovative healthcare interventions for non-communicable diseases
- Destination 3: HORIZON-HLTH-2027-02-DISEASE-14-two-stage: Clinical trials for advancing innovative interventions for neurodegenerative
- Destination 6: HORIZON-HLTH-2027-01-IND-01: Development of cell-free protein synthesis platforms for discovery and/or production of biologicals
- Destination 4: HORIZON-HLTH-2027-01-CARE-02: Personalised approaches to reduce risks from Adverse Drug Reactions due to administration of multiple medications
- Destination 5: HORIZON-HLTH-2027-02-TOOL-01-two-stage: Development of predictive biomarkers of disease progression and treatment response by using AI methodologies for chronic non-communicable diseases
Eduard Garcia
Founder & Commercial Director at AxioTechBio
Paris, France
Project cooperation
- Partner seeks Consortium/Coordinator
- Destination 6: HORIZON-HLTH-2027-02-IND-02-two-stage: Portable and versatile Point-of-care diagnostics
- Destination 5: HORIZON-HLTH-2027-03-TOOL-02: Advancing bio-printing of living cells for regenerative medicine
- Destination 3: HORIZON-HLTH-2027-02-DISEASE-01-two-stage: Innovative healthcare interventions for non-communicable diseases
- Destination 2: HORIZON-HLTH-2027-01-ENVHLTH-MISSCLIMA-03: Tools and technologies to support health adaptation to climate change
- Destination 5: HORIZON-HLTH-2027-03-TOOL-08: Towards the next generation of frontier Artificial Intelligence models for healthcare
- Destination 3: HORIZON-HLTH-2027-01-DISEASE-06: Development of monoclonal antibodies to prevent and treat infections from Flaviviruses
- Destination 3: HORIZON-HLTH-2027-01-DISEASE-08: Development of innovative antimicrobials against pathogens resistant to antimicrobials
- Destination 3: HORIZON-HLTH-2027-02-DISEASE-14-two-stage: Clinical trials for advancing innovative interventions for neurodegenerative
- Destination 1: HORIZON-HLTH-2027-01-STAYHLTH-01: Addressing disabilities through the life course to support independent living and inclusion
- Destination 5: HORIZON-HLTH-2027-03-TOOL-04: Virtual Human Twins (VHTs) for integrated clinical decision support in prevention and diagnosis
- Destination 6: HORIZON-HLTH-2027-01-IND-01: Development of cell-free protein synthesis platforms for discovery and/or production of biologicals
- Destination 3: HORIZON-HLTH-2027-01-DISEASE-05: Development of novel small molecule antiviral therapeutics for pathogens with epidemic potential
- Destination 3: HORIZON-HLTH-2027-01-DISEASE-10: Prevention and management of chronic non-communicable diseases in children and young people (GACD)
- Destination 4: HORIZON-HLTH-2027-01-CARE-02: Personalised approaches to reduce risks from Adverse Drug Reactions due to administration of multiple medications
- Destination 2: HORIZON-HLTH-2027-01-ENVHLTH-02: Integrating climate-related exposures into the human exposome and characterising its changes in response to climate change
- Destination 3: HORIZON-HLTH-2027-01-DISEASE-07: Development of monoclonal antibodies to prevent and treat infections from Filo-, Nairo-, Phenui-, Picorna- and Toga viruses
- Destination 5: HORIZON-HLTH-2027-02-TOOL-01-two-stage: Development of predictive biomarkers of disease progression and treatment response by using AI methodologies for chronic non-communicable diseases
Marco Sideri
Project Manager at YourDATA
Cagliari, Italy